Abstract
A highly sensitive, spectrofluorometric method was developed for the determination of drotaverine HCl in pharmaceutical preparations. The proposed method is based on the measurement of the native fluorescence of the drug in 0.1 M H2SO4 at emission 465 nm after excitation at 295 nm. The relative fluorescence intensity-concentration plot was rectilinear over the range of 0.16–4 µg·ml−1, with good correlation (r = 0.9999) and a lower limit of detection (LOD) of 0.032 µg·ml−1. The proposed method was successfully applied for the determination of drotaverine HCl in tablets and ampoules with a recovery percentage of 100.42 ± 0.601,99.83 ± 0.82 and 99.43 ± 1.08, respectively, which were in accordance with those obtained by a compendial method.
Notes
Each value is the average of three separate determinations.
Figures between parentheses are the tabulated t & F values at p = 0.05.
Each result is the average of 3 separate determinations.
Figures between parentheses are the tabulated t & F values at p = 0.05.
a Mean ± SD, (n = 3).